Intelligent Bio Solutions Validates Security with Zero Vulnerabilities Ahead of FDA 510(k) Bid
Intelligent Bio Solutions completed penetration testing for its upcoming FDA 510(k) submission, identifying no major security vulnerabilities and implementing enhanced encrypted identification tags and firmware safeguards. These upgrades strengthen the company’s regulatory position for U.S. drug screening market entry, potentially unlocking multi-billion-dollar revenue opportunities.
1. Penetration Testing Validates Security Posture
Intelligent Bio Solutions conducted independent penetration testing on its drug screening platform as part of its upcoming FDA 510(k) submission, with no major vulnerabilities identified and all critical systems verified for robustness.
2. Implementation of Enhanced Security Features
The company integrated enhanced encrypted identification tags and reinforced firmware safeguards that restrict unauthorized updates and protect donor data, fortifying the system against cyber threats.
3. Positioning for FDA 510(k) Clearance and Market Entry
By addressing evolving FDA cybersecurity requirements early, the company has strengthened its regulatory submission and positioned its Intelligent Fingerprinting Drug Screening System for clearance that could open access to the multi-billion-dollar U.S. drug screening market.